ACTIVITY OVERVIEW | This Webcast contains video and downloadable slides from the symposium The Evolving Management of Neuroendocrine Tumors: An Exploratory Voyage, a prIME Oncology educational activity that was held at the 2011 Oncology Annual Meeting in Chicago, Illinois, United States. |
FACULTY | Chair
James C. Yao, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas, United States
Faculty
Marianne Pavel, MD
Charité Hospital
Berlin, Germany
Ramon Salazar, MD, PhD
L’Hospitalet de Llobregat
Catalan Institute of Oncology
Barcelona, Spain
Marco Volante, MD, PhD
University of Turin
San Luigi Hospital
Turin, Italy
|
TARGET AUDIENCE | This educational activity is intended for medical oncologists, radiation oncologists, endocrinologists, gastroenterologists, pulmonologists, pathologists, radiologists, surgeons, and other healthcare providers involved and/or interested in the management of patients with neuroendocrine tumors. This meeting is restricted to healthcare professionals based outside of the United States. |
|
|
 |
|
Expert Discussion
|
 |
|
Downloadable Slides
|
|
 |
TOPICS | Introduction
James C. Yao, MD
Histopathologic classification and staging: Have we underestimated NET’s malignant potential?
Marco Volante, MD, PhD
The role of imaging and biomarkers
Marianne Pavel, MD
Historical management: Where are the unmet needs?
Ramon Salazar, MD, PhD
Contemporary management: What have we learned from phase III trials?
James C. Yao, MD |
LEARNING OBJECTIVES | After successful completion of this educational activity, participants should be able to:
- Describe the biology and pathogenesis of neuroendocrine tumors, focusing on signaling pathways that are potential targets of new molecular therapeutics
- Discuss the epidemiology of neuroendocrine tumors
- Evaluate the role of imaging and clinical biomarkers in the management of neuroendocrine tumors
- Assess currently available management options and treatment modalities for patients with neuroendocrine tumors
- Recognize the role and importance of multidisciplinary specialists in the management of patients with neuroendocrine tumors
- Evaluate recent clinical trial data on the use of emerging therapies in patients with neuroendocrine tumors, and assess the practical implications of this data
|
|
|
|
SUPPORT | Support for this activity is provided by Novartis Oncology.
|
|
